Ipsen S.A. (IPSEY) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Boulogne-Billancourt, France. The current CEO is David Loew.
IPSEY has IPO date of 2012-08-03, 5,358 full-time employees, listed on the Other OTC, a market capitalization of $64.99B.
Ipsen S.A. is a global biopharmaceutical company headquartered in France that develops and markets prescription drugs and consumer healthcare products across oncology, neuroscience, gastroenterology, and rare diseases. The company's oncology portfolio includes Cabometyx for renal cell and hepatocellular carcinoma, Onivyde for pancreatic cancer, and Cometriq for medullary thyroid cancer, while its specialty care offerings encompass Somatuline for neuroendocrine tumors, Dysport for neurological and aesthetic applications, and NutropinAq for growth hormone deficiency. Ipsen also maintains a significant gastroenterology and consumer healthcare business with products such as Smecta for diarrhea, Forlax for constipation, and Tanakan for cognitive disorders, along with established partnerships with leading biotechnology firms including Exelixis, Blueprint Medicines, and Galderma. Founded in 1929, the company leverages its diversified product portfolio and strategic collaborations to serve patients in multiple therapeutic areas worldwide.
